COVID-19; This spontaneous case was reported by a patient and describes the occurrence of COVID-19 (COVID-19) in a 32-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Hypothyroidism and Hashimoto's disease. Concomitant products included LEVOTHYROXINE, LIOTHYRONINE (NP THYROID) and TRAMADOL for an unknown indication.    On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced COVID-19 (COVID-19). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) from 21-May-2022 to 25-May-2022 for COVID-19 treatment, at an unspecified dose and frequency. At the time of the report, COVID-19 (COVID-19) outcome was unknown.            It was reported that patient was taking other medications or products within 2 weeks of starting COVID-19 treatment.  Patient previously received a COVID-19 Vaccine. Device Date : 30May2022 After stopping paxlovid, the patient experienced Sore throat, body aches, congestion, headache.  Company comment This spontaneous case reported by a patient, concerns a 32-year-old female patient with concurrent illness with Hypothyroidism and Hashimoto's disease, who experienced the unexpected, non serious AESI of covid 19, unknown days after receiving the 3 dose of mRNA-1273 vaccine in the covid 19 vaccination series. Patient previously received a COVID-19 Vaccine. Further details of previous vaccination doses was not reported. It was reported that the patient was treated with Nirmatrelvir, Ritonavir (Paxlovid), for 5 days from 21-May-2022 to 25-May-2022 for COVID-19 treatment, at an unspecified dose and frequency. Outcome of this event of Covid 19 was not provided. Concurrent illness Hypothyroidism and ongoing Covid 19 pandemia are confounders. On 30-May-2022, 5 days after stopping paxlovid, the patient experienced Sore throat, body aches, congestion, headache. These events were resolving. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report. Event seriousness assessed per Medical judgement.; Sender's Comments: This spontaneous case reported by a patient, concerns a 32-year-old female patient with concurrent illness with Hypothyroidism and Hashimoto's disease, who experienced the unexpected, non serious AESI of covid 19, unknown days after receiving the 3 dose of mRNA-1273 vaccine in the covid 19 vaccination series. Patient previously received a COVID-19 Vaccine. Further details of previous vaccination doses was not reported. It was reported that the patient was treated with Nirmatrelvir, Ritonavir (Paxlovid), for 5 days from 21-May-2022 to 25-May-2022 for COVID-19 treatment, at an unspecified dose and frequency. Outcome of this event of Covid 19 was not provided. Concurrent illness Hypothyroidism and ongoing Covid 19 pandemia are confounders. On 30-May-2022, 5 days after stopping paxlovid, the patient experienced Sore throat, body aches, congestion and headache. These events were resolving. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report. Event seriousness assessed per Medical judgement.